Cite

    I Pavord et al.. “S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study.” Thorax, vol. 73, n.d., p. A48. http://access.bl.uk/ark:/81055/vdc_100144731137.0x000042